Sunday, December 08, 2019 2:45:43 PM
Rosenberg said he is speeding up enrollment to 1 patient per cohort / every 3 weeks in the other Viral TCR NeoAntigen Trial per video April 2019.''
A few days around the estimated start date was the 9th and now it has been changed to the 11th. But this has been the case for the last few months (since Sept).
''While you wait to the year 2028
Dr Drew Deniger + Ziopharm is staffing up with Ana Beatriz Korngold, Tom Spencer, + others in Houston... to launch ZIOP's own controlled TCR NeoAntigen Trial... do you think it will be Phase 1?... or Phase 2/3? and will it be as slow as Govt Longitudinal study?... if they start showing efficacy... game set match - Jon Doe Uk, innit?''
Knowing this company I wouldn't expect much. If the trial does happen, I will likely be a PhI and should move slightly faster (once open and enrolling) than the one at the NCI. Also, being an open label (I assume) they can report data when they see fit.
Recent TCRT News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:46:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:44:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:05:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:43:20 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:58:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:45:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:30:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:25:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 01:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 12:30:01 PM
- Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives • GlobeNewswire Inc. • 11/14/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2023 09:34:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/01/2023 04:20:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:37:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:16:29 PM
- Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives • GlobeNewswire Inc. • 08/14/2023 08:05:34 PM
- Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies • GlobeNewswire Inc. • 06/29/2023 11:00:53 AM
- Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/25/2023 09:00:52 PM
- Alaunos Therapeutics Reports First Quarter 2023 Financial Results • GlobeNewswire Inc. • 05/10/2023 11:00:17 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM